Fibrosis is a convergent, organ-agnostic pathology driven by persistent myofibroblast activation and dysregulated extracellular-matrix remodeling. We develop precision therapeutics directed at the activated stromal compartment.
Across tissues, chronic injury and inflammatory signaling drive the trans-differentiation of resident fibroblasts into activated myofibroblasts. These cells deposit and crosslink extracellular matrix, stiffen the parenchyma, and reinforce their own activation through paracrine feedback — producing progressive, frequently irreversible loss of organ function.
Sustained tissue stress and pro-fibrotic cytokine signaling prime the stromal niche.
Resident fibroblasts adopt a contractile, matrix-secreting phenotype and remodel the ECM.
Crosslinked collagen and mechano-feedback perpetuate activation, driving organ dysfunction.
Conventional antifibrotics act broadly and are dose-limited by systemic toxicity. Viventia's strategy is to engage the activated stromal compartment with precision — targeting pharmacological activity at sites of active fibrogenesis while preserving normal tissue homeostasis and host immunity.
Directed at markers enriched on activated, disease-associated fibroblasts and largely absent from quiescent stroma in healthy adult tissue.
Because activated myofibroblasts are a shared endpoint of fibrosis, a single mechanistic approach is extensible across multiple organ systems.
Quantitative pharmacodynamic and patient-stratification biomarkers anchor a closed-loop, evidence-led clinical strategy.
A platform addressing fibroinflammatory indications that share a common stromal biology and carry high unmet need.
Interstitial and perivascular fibrosis driving HFpEF progression — no approved antifibrotic.
Progressive parenchymal scarring; current agents slow but do not reverse decline.
Hepatic stellate-cell activation and bridging fibrosis advancing toward cirrhosis.
Tubulointerstitial fibrosis as the common pathway to progressive renal failure.
Multi-organ fibrosis with limited disease-modifying options.
Our first asset advances the platform's precision-targeting strategy toward the clinic. Additional programs remain in earlier discovery.
VIV-01 is in active asset development. All programs are pre-clinical.
We welcome conversations with investors and pharma/biotech partners. Detailed materials are available under confidentiality.
team@viventia.bio